Date | Title | Description | |
---|---|---|---|
26 Jun 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
24 Jun 2024 | On business and financial situation | ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth | Download |
08 May 2024 | On P&L | The Company releases the press release related to the first three months of 2024 financial results | Download |
08 May 2024 | On P&L | The Company releases the first three months 2024 financial results presentation | Download |
25 Apr 2024 | On business and financial situation | ROVI announces agreement to manufacture pre-filled syringes | Download |
Pages
Date | Title | Description | |
---|---|---|---|
05 Jul 2021 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the second quarter of 2021 | Download |
02 Jul 2021 | Other relevant information | The Company informs about the dividends payment | Download |
02 Jul 2021 | Other relevant information | The Company informs about the dividends payment | Download |
17 Jun 2021 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
13 May 2021 | On business and financial situation | The company releases the press release related to first quarter 2021 financial results | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |